Antihypertensive Response to Losartan and Genetic Polymorphisms

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Antihypertensive Agents; Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• Both gender less than 60 years old, with mild-moderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP < 180/110)

• Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit

• Patient in therapeutic wash out for 6 months

• Patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases

• Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method

• BMI < 30 for men and < 28 for women

Exclusion Criteria:

• Secondary or malignant hypertension, Na <130 mmol/l, K >5,5 mmol/l, or < 3,0 mmol/l

• Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery

• Pregnant, breast feeding

• History of nephropathy, metabolic disease, liver disease

• Alcohol or drug abuse

• History of angioedema

• Has a known hypersensibility to study drug(s)